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Summary
Sugar biosynthesis cassette genes have been used
to construct plasmids directing the biosynthesis of
branched-chain deoxysugars: pFL942 (NDP-L-mycar-
ose), pFL947 (NDP-4-deacetyl-L-chromose B), and
pFL946/pFL954 (NDP-2,3,4-tridemethyl-L-nogalose).
Expression of pFL942 and pFL947 in S. lividans 16F4,
which harbors genes for elloramycinone biosynthesis
and the flexible ElmGT glycosyltransferase of the el-
loramycin biosynthetic pathway, led to the formation of
two compounds: 8--L-mycarosyl-elloramycinone and
8-demethyl-8-(4-deacetyl)--L-chromosyl-tetrace-
nomycin C, respectively. Expression of pFL946 or
pFL954 failed to produce detectable amounts of a
novel glycosylated tetracenomycin derivative. Forma-
tion of these two compounds represents examples of
the sugar cosubstrate flexibility of the ElmGT glyco-
syltransferase. The use of these cassette plasmids
also provided insights into the substrate flexibility of
deoxysugar biosynthesis enzymes as the C-methyl-
transferases EryBIII and MtmC, the epimerases OleL
and EryBVII, and the 4-ketoreductases EryBIV and
OleU.
Introduction
Many bioactive natural products are glycosylated by
one or more deoxysugar saccharide chains of variable
sugar length. These include important antibiotics (ery-
thromycin), antifungals (amphotericin B), antiparasites
(avermectins), and anticancer drugs (doxorubicin).
These deoxysugar moieties participate in the molecular
recognition of the drug target site and therefore they
are usually very important for the biological activity of
many natural products [1]. The glycosylation steps usu-
ally occur late during biosynthesis by transferring the
deoxysugar to the aglycon from an NDP-sugar acti-
vated form [2–4]. A great majority of the deoxysugars in
natural products belong to the 6-deoxyhexoses family
(6DOH), which includes at least 80 different representa-*Correspondence: jrohr2@uky.edu; cmendezf@uniovi.estives in metabolites from various sources [1–3]. These
deoxysugars can be classified as neutral sugars,
aminosugars, or branched-chain sugars [2]. Deoxysu-
gar biosynthesis occurs through nucleoside diphos-
phate-activated hexoses (mainly D-glucose) via a
4-keto-6-deoxy intermediate. The two earliest biosyn-
thetic steps are common to the biosynthesis of all
deoxysugars, and it involves the activation of D-glu-
cose into NDP-D-glucose and a further dehydration
step generating NDP-4-keto-6-deoxy-D-glucose. These
two reactions are catalyzed by an NDP-D-hexose syn-
thase and a NDP-D-hexose-4,6-dehydratase [2, 3]. Fur-
ther enzymatic reactions (deoxygenations, transamina-
tions, C-, N-, or O-methylations) affecting carbon atoms
at positions 2, 3, 4, or 5 in the hexose carbon backbone
will introduce different modifications increasing the
structural diversity of the family [2, 3]. D- and L-stereo-
isomeric forms of many 6DOH also exist as a result of
the action of a 5- or a 3,5-epimerase.
In the last several years, a number of deoxysugar bio-
synthetic gene clusters from antibiotic-producing or-
ganisms have been described. In a few cases, biosyn-
thetic gene clusters for the same 6DOH have been
characterized from different producer organisms. For
example, this is the case of the D-desosamine gene
cluster, which has been characterized from streptomy-
cetes producing erythromycin A [5, 6], oleandomycin
[7, 8], pikromycin [9], and megalomicin [10], and is also
true for D-olivose, whose gene cluster has been char-
acterized in the mithramycin [11, 12], chromomycin
[13], urdamycin [14], and landomycin [15] producers.
The gene cluster for L-oleandrose has been also char-
acterized in the oleandomycin [7, 8] and avermectin
[16] producers, and the L-mycarose cluster in pro-
ducers of erythromycin [5, 6], megalomycin [10], and
tylosin [17–20]. In vitro assays for testing the activity of
many of the enzymes involved in deoxysugar biosyn-
thesis or glycosyltransfer reactions have been ham-
pered by the unavailability of suitable activated deoxy-
sugars, although in a few cases it was possible to
assign putative roles to the different enzymes in deoxy-
sugar biosynthesis by carrying out enzymatic assays to
demonstrate the activity of such enzymes and to verify
their substrates [19–25]. However, only in the case of
L-epivancosamine from the producer of the glycopep-
tide chloroeremomycin [26] was the complete in vitro
reconstitution of the pathway for the biosynthesis of a
6DOH reported. More frequently, functions of enzymes
of deoxysugar pathways were assigned on the basis
of similarities with related enzymes in databases and
through the analysis of the compounds accumulated
by mutants affected in selected deoxysugar genes [5,
6, 9, 12–15, 17, 27–30].
An important aspect for the generation of novel gly-
cosylated derivatives is to provide the host strain with
the capability of synthesizing various deoxysugars,
which then could be potentially transferred by existing
glycosyltransferases of the host strain to the aglycon.
Several plasmids containing a set of genes involved
in 6DOH biosynthesis and capable of directing the bio-
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iready constructed and heterologously expressed: L-dau-
nosamine [31], L-olivose [8], L-oleandrose [8, 32], and i
RD-desosamine [33]. In all these cases, a native DNA
fragment was cloned from the chromosome of the pro- e
iducer organism into the appropriate vector. More re-
cently, a “plug and play” plasmid system has been con- n
dstructed allowing the easy and quick replacement of
specific sugar biosynthesis genes by other related o
igenes, thus introducing or removing enzymatic activi-
ties and facilitating the generation of novel deoxysugar d
fmoieties [34]. This plasmid vector, pLN2, containing
genes from the L-oleandrose biosynthesis of the olean- 1
tdomycin biosynthetic gene cluster from Streptomyces
antibioticus, has been used to endow the recipient host b
ostrain with the ability of synthesizing different deoxysu-
gars [34]. C
sGeneration of novel glycosylated compounds re-
quires the availability of glycosyltransferases with some
degree of flexibility. In the last several years, increasing C
evidence suggested the existence of a certain degree P
of “sugar cosubstrate flexibility” of glycosyltransfer- T
ases involved in the biosynthesis of secondary metabo- T
lites, and some examples have been reported in which L
various deoxysugars have been transferred to the agly- t
con [12, 25, 28, 32–40]. One of these glycosyltransfer- g
ases, the elloramycin glycosyltransferase ElmGT has m
been shown to be especially “flexible” accepting dif- h
ferent L- and D-deoxysugars and being also able to s
transfer a disaccharide [34, 40–43]. An alternative t
method for increasing the glycosylation pattern of a e
compound is the so-called “in vitro glycorandomiza- g
tion,” This approach uses an NDP-D-hexose synthase c
for activating a library of chemically synthesized sugar- u
1-phosphate precursors that can be now used for gly- S
cosylation assays [44–46]. p
Here we report the use of deoxysugar biosynthesis p
genes to construct plasmids directing the biosynthesis g
of different branched-chain deoxysugars and the for- e
mation of two tetracenomycin derivatives taking advan- w
tage of the high flexibility of the ElmGT glycosyltrans- t
ferase. The results presented here reveal new insights c
about 6DOH biosynthetic pathways, including flexibility m
for the use of several sugar genes and à la carte de- t
signed pathway deviations in order to obtain the de- m
sired final activated branched-chain deoxysugar. In this s
way, it was also possible to establish some rules about (
the use of these deoxysugar genes for combinatorial (
biosynthesis. T
c
TResults and Discussion
t
gL-Nogalose (L-NOG) or its 2,3,4-tridemethyl-derivative,
L-mycarose (L-MYC) or its 3-O-methyl-derivative cladi- p
nose, and L-chromose B (L-CHR, also called L-olivomy-
cose) are three deoxysugars occurring in a number of p
Tbioactive natural products (Figure 1). They are all
branched-chain deoxysugars possessing a C-methyl i
Agroup at C-3 of the hexose carbon backbone. Besides
the difference in the functionalization of the OH groups, O
aL-NOG and L-CHR differ in the oxygenation state at
C-2, L-NOG being a 6-deoxyhexose and L-CHR a 2,6- p
tdideoxyhexose. L-MYC and L-CHR, both being 2,6-ideoxyhexoses, differ in that the 4-OH group of L-CHR
s acetylated and, more importantly, in the stereochem-
stry at C-3, which is S-configurated in L-CHR and
-configurated in L-MYC. In the experiments describ-
d below, we show the construction of plasmids direct-
ng the biosynthesis toward the nonmethylated and
onacetylated derivatives, namely L-MYC, 2,3,4-tri-O-
emethyl-L-NOG, and 4-O-deacetyl-L-CHR (Figure 1),
f these three branched-chain sugars. Assaying their
ncorporation to an aglycon tested formation of these
eoxysugars. To achieve this, we expressed the dif-
erent “sugar plasmids” into Streptomyces lividans
6F4, which harbors cos16F4 [47]. Cosmid 16F4 con-
ains part of the elloramycin gene cluster and it has
een shown that its expression leads to the production
f the elloramycin aglycon, 8-demethyl-tetracenomycin
(8DMTC) [47] and also contains the elmGT glyco-
yltransferase encoding gene [42].
onstruction of an L-Mycarose-Synthesizing
lasmid and Generation of L-Mycarosyl-
etracenomycin C
o generate a plasmid encoding the biosynthesis of
-MYC, we expressed all genes under the control of
wo erythromycin resistance promoters cloned in diver-
ent directions. Two genes from the mithramycin cluster,
tmD (NDP-D-glucose synthase) and mtmE (NDP-D-
exose-4,6-dehydratase) [11] were subcloned down-
tream of one of the promoters and oleV (2,3-dehydra-
ase), oleW (3-ketoreductase), eryBIV (4-ketoreductase),
ryBIII (C-3-methyltransferase), and oleL (3,5-epimerase)
enes [5, 6, 8] subcloned under the control of the se-
ond divergent promoter. Each gene was flanked by
nique restriction sites, which do not frequently cut
treptomyces DNA (Figure 2). The final construct,
FL821, contains the same enzymatic functions as the
reviously described pLNBIV [34], but with a different
enetic organization and with the incorporation of the
ryBIIImethyltransferase gene (Figure 2). When pFL821
as expressed in S. lividans 16F4, no L-mycarosyl-
etracenomcyin C (LMYC-TCMC) was detected, but it
aused the formation of two different compounds. The
ajor one (peak 3 in Figure 3A) showed the same reten-
ion time as a pure sample of L-digitoxosyl-tetraceno-
ycin C (LDIG-TCMC) and with m/z ions 459 (corre-
ponding to the 8DMTC aglycon fragment) and 589
corresponding to LDIG-TCMC). The second minor peak
peak 2 in Figure 3A) showed the same m/z ions as LDIG-
CMC and identical mobility to that of L-olivosyl-tetra-
enomycin C (LOLV-TCMC). LDIG-TCMC and LOLV-
CMC represented approximately 35% and 13% of all
etracenomycins produced, respectively. These two
lycosylated derivatives were also generated in similar
roportions when pLNBIV was used [34, 43].
The lack of formation of L-MYC can probably be ex-
lained if the C-methyltransferase EryBIII acts like the
ylC3 C-methyltransferase, namely on an NDP-D-sugar
ntermediate with an axial hydroxyl group at C-3 [19].
s a consequence of the action of 3-ketoreductase
leW [24, 34], an intermediate not with an axial but with
n equatorial 3-OH group is expected when using
FL821. Therefore we concluded that the C-methyl-
ransferase EryBIII was probably unable to act on the
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1711Figure 1. Structures of Glycosylated Deriva-
tives of 8-Demethyl-Tetracenomycin C (R1=H)
and Elloramycinone (R1=CH3)
Black sugar moieties: constructed and de-
scribed in earlier publications (see references
in text); blue sugar moieties: newly constructed
derivatives with branched deoxysugars (this
publication); red sugar moiety: yield too low
to be detected.intermediate produced by the strain expressing pFL821.
To generate a sugar intermediate with the appropriate
axial hydroxyl group at C-3, we replaced the oleW 3-keto-
reductase gene in pFL821 by its counterpart eryBII [6,
29]. This is a 3-ketoreductase involved in L-MYC bio-
synthesis, which is supposed to introduce a hydroxyl
group at C-3 with axial configuration. Such an enzy-
matic function has been proved by in vitro assays with
the EryBII-homologous reductase TylC1 [20]. Again, af-
ter expressing the resultant construct pFL822 (Figure 2)
into S. lividans 16F4, the same two peaks (peaks 3 and
2 respectively, in Figure 3B), corresponding to LDIG-
TCMC (79%) and LOLV-TCMC (12%), were identified.
As expected, the production of LDIG-TCMC was higher
than when using pFL821 due to the gene combination
present in pFL822, since the action of the 3,5-epi-
merase OleL and the 4-ketoreductase EryBIV on theFigure 2. Genetic Organization of Deoxysugar Biosynthesis Gene
Cassettes in the Different Plasmids
Genes in gray were not replaced in the different plasmids. Colored
genes show those that were replaced in the different plasmids. Ab-
breviations: SYN, NDP-D-glucose synthase; 4,6-DH, 4,6-dehydra-
tase; 2,3-DH, 2,3-dehydratase; 3-KR, 3-ketoreductase; 4-KR, 4-keto-
reductase; C-MT, C-methyltransferase; EP, epimerase; and P, eryth-
romycin resistance promoter.EryBII product should efficiently render L-digitoxose.
The fact that no L-mycarosyl-derivative was produced
prompted us eventually to assume that the failure to
produce this deoxysugar could be due to OleL, which
is a 3,5-epimerase acting on a C-3 nonmethylated inter-
mediate [8]. However, the EryBIII (in pFL822)-mediated
C-3 methylation could hamper the epimerization event.
Therefore, we replaced the oleL gene in pFL822 with
the eryBVII epimerase gene [5, 6, 29], resulting in
pFL942 (Figure 2). Analysis of cultures of S. lividans 16F4
harboring pFL942 showed the presence of a new com-
pound (peak 9 in Figure 3C) corresponding to L-mycar-
osyl-elloramycin (LMYC-ELM), together with LDIG-
TCMC (peak 3) and small amounts of LOLV-TCMC
(peak 2). HPLC-MS analysis of the corresponding peaks
showed m/z values of 617, 589, and 589 respectively,
which match the expected masses for these three com-
pounds. In the case of LMYC-ELM, the fragmentation
ion corresponding to the aglycon (m/z 473, M-H+) indi-
cates that the aglycon is probably methylated. This
suggests that this glycosylated derivative contains el-
loramycinone as the aglycon and not 8-demethyl-tetra-
cenomycin C (8DMTC), usually found as aglycon of
cosmid16F4-mediated glycosylation products. Ellora-
mycinone differs from 8DMTC in that it has a 12a-OCH3
instead of a 12a-OH group. This 12a-O-methylation can
be explained, because cos16F4 contains a gene coding
for an O-methyltransferase, ElmMIV, which acts during
elloramycin biosynthesis usually once 8DMTC has
been glycosylated (F.L., unpublished data). Confirm-
ation of the structure of this new compound was
achieved after its purification by preparative HPLC and
structural elucidation by MS and NMR (see below). The
L-DIG-, L-MYC-, and L-OLV-glycosylated derivatives rep-
resented approximately 27%, 13%, and 10%, respec-
tively, of the total tetracenomycins produced. The prefer-
ence of ElmGT for L-DIG rather than L-MYC probably
reflects a preference of ElmGT for unmethylated sub-
strates rather than methylated ones, since ElmGT uses
NDP-L-rhamnose, an unmethylated deoxysugar, as its
natural sugar cosubstrate. The low transfer of L-MYC
using this plasmid system does not indicate a low effi-
ciency in the formation of L-MYC. Using pFL942 in an-
other system, we have shown that L-MYC is efficiently
transferred by the EryBV glycosyltransferase (which
Chemistry & Biology
1712normally transfers L-mycarose) with the conversion of a
uapproximately 65% of erythronolide B into L-mycaro-
syl-erythronolide B (F.L., unpublished data). e
(To discard the possibility that genes present in the
S. lividans 16F4 host strain were participating in the t
dbiosynthesis of L-MYC, several control experiments
were run using various derivatives of pFL942, in which m
meryBIV (pFL952), eryBVII (pFL944), eryBIII (pFL953), or
eryBII + oleV (pFL946) were independently deleted (Fig- 4
Lure 2). In all four cases, no L-MYC-containing ellora-
mycin derivative was detected (data not shown). These c
experiments clearly excluded the participation of host-
mediated enzymatic activities in the formation of L-MYC. T
aOnce we got a plasmid (pFL942) able to direct the
biosynthesis of L-mycarose, we wondered if we could (
4generate L-mycarose using another combination of
genes. Thus, we analyzed the possibility of using oleU s
rfor this purpose. OleU is a 4-ketoreductase involved in
L-olivose biosynthesis [8], which renders the final C-4 m
ahydroxy group into the equatorial position, thus estab-
lishing the same stereochemistry as EryBIV does. It has s
mbeen shown that OleU possesses some substrate flexi-
bility [40]. Therefore, we replaced eryBIV in pFL942 by f
EoleU (generating pFL943) (Figure 2). Upon transforma-
tion of pFL943 into S. lividans 16F4, no LMYC-ELM was e
iformed. However, three different peaks were observed.
One of them corresponded to LOLV-TCMC (peak 2 in
tFigure 3D) with approximately 23% conversion of theFigure 3. HPLC Analyses of Cultures of S. lividans 16F4
HPLC analyses of cultures of S. lividans 16F4 harboring (A) pFL821, (B) pFL822, (C) pFL942, (D) pFL943, (E) pFL945, and (F) pFL947. Peaks
corresponding to the different tetracenomycins/elloramycins are indicated as follows: D-glucosyl-tetracenomycin C (1); L-olivosyl-tetraceno-
mycin C (2); L-digitoxosyl-tetracenomycin C (3); 4-deacetyl-L-chromosyl-tetracenomycin C (4); D-olivosyl-tetracenomycin C (5); 8-demethyl-
tetracenomycin C (6); L-digitoxosyl-elloramycin (7); 4-deacetyl-L-chromosyl-elloramycin (8); L-mycarosyl-elloramycin (9); elloramycin (10);
3#,4#-demethoxy-elloramycin (11).glycon. The other two peaks (peaks 10 and 11 in Fig-
re 3D) showed retention times and masses identical to
lloramycin (peak 10) and 3#,4#-demethyl-elloramycin
peak 11). Both compounds posses L-rhamnose at-
ached to the elloramycinone aglycon and they only
iffer in the degree of methylation of the sugar, ellora-
ycin being permethylated and 3#,4#-demethyl-ellora-
ycin lacking the methyl groups at positions 3 and
of the L-rhamnose moiety. Therefore, in total, the
-rhamnosyl derivatives account for 31% of all tetra-
enomycins.
The above experiments designed to generate LMYC-
CMC have allowed us to draw up some conclusions
bout the specificity and flexibility of some of the genes
and their products) used for these constructs (Figure
). On one hand, the EryBIV 4-ketoreductase pos-
esses a certain relaxed specificity, since it is able to
educe either C-3 methylated or unmethylated inter-
ediates, the latter ones with different stereochemistry
t C-3. However, its counterpart OleU showed lower
ubstrate flexibility, since it is unable to act on C-3
ethylated intermediates. It can also be concluded that
or generating C-3 methylated sugar derivatives, the
ryBVII epimerase is more appropriate than the OleL
pimerase, since OleL cannot epimerize C-5 once C-3
s already methylated.
One further and interesting aspect coming out from
he experiments with pFL943 is that the formation of
Glycosylation in Bioactive Compounds
1713Figure 4. Proposed Pathways for the Biosynthesis of the Different Deoxysugars Directed by the Plasmids Described in This Work
Pathways producing branched-chain deoxysugars are colored. Genes unable to carry out the indicated steps are shown in brackets. Plasmids
leading to the formation of the different deoxysugars are indicated below the name of the corresponding deoxysugar. LNOG, 2,3,4-tride-
methyl-L-nogalose; LOLV, L-olivose; LRHA, L-rhamnose; LDIG, L-digitoxose; LMYC, L-mycarose; and L-CHR, 4-deacetyl-L-chromose B.LRHA-ELM and LOLV-TCMC requires two different epi-
merization events: 3,5-epimerization in the case of
LRHA-ELM and 5-epimerization in the case of LOLV-
TCMC. There are several possibilities to explain the for-
mation of these two different sugars in the presence
of a unique epimerase, EryBVII (which is supposed to
catalyze a 5-epimerization in L-MYC biosynthesis in
Saccharopolyspora erythraea). First, it is possible that
another epimerase in the host strain exists that cata-
lyzes the 3,5-epimerization. This possibility could be
ruled out, since when we used pFL1012 (Figure 2), a
derivative of pFL943 lacking eryBVII, neither LRHA-
TCMC nor LOLV-TCMC was produced (data not shown).
A second possibility would be that EryBVII could act
both as a 5- (in the formation of LOLV-TCMC) and as a
3,5-epimerase (in the formation of LRHA-ELM) depend-
ing on the substrate intermediates. A similar situation
has been demonstrated for the EvsA epimerase, which
is involved in the biosynthesis of the 4-epi-L-vanco-
samine moiety decorating chloroeremomycin. It has
been shown by in vitro enzymatic assays [26, 48] that
EvsA can act both as a 5- or a 3,5-epimerase when
using different substrates. A final possibility would be
that, after the 5-epimerization event, both C-5 and C-3,5
epimers could coexist due to a C-3 to C-4 tautomerism
equilibrium, one of them being a better substrate for
the OleU 4-ketoreductase. We have recently proposed
this mechanism to explain the formation of LDIG-TCMC
by pLNBIV [43].
Construction of a 4-Deacetyl-L-Chromose B
(4-Deacetyl-L-Olivomycose)-Synthesizing Plasmid
and Generation of 8-Demethyl-8-(4-Deacetyl-L-
Chromosyl B)-Tetracenomycin C
L-chromose B, L-CHR (also designated as L-olivomy-
cose, Figure 1) is a neutral and branched-chain sugarpresent in the aureolic acid group antitumor drugs oli-
vomycin and chromomycin [13, 49, 50]. We were inter-
ested in constructing a plasmid directing the biosyn-
thesis of 4-deacetyl-L-CHR and in testing if ElmGT was
also able to transfer this sugar. As a first step and, since
4-deacetyl-L-CHR only differs from L-MYC in the ste-
reochemistry at C-3, we replaced in pFL942 eryBII with
oleW. This was based on the assumption that the pro-
duct of the latter gene could generate an intermediate
with the appropriate stereochemistry at C-3 as a sub-
strate for the C-methyltransferase EryBIII, thus generat-
ing 4-deacetyl-L-CHR. Expression of this construct
(pFL945; Figure 2) in S. lividans 16F4 gave rise to the
formation of LDIG-TCMC (peak 3 in Figure 3E; 34%
conversion) and LMYC-ELM (peak 9 in Figure 3E; 8%
conversion) but no 4-deacetyl-LCHR-TCMC was de-
tected. Formation of LMYC-ELM probably implies that
an intermediate with an axial C-3 hydroxyl group (nor-
mal substrate for EryBIII) is being generated via a C-3
to C-4 tautomerization on the product of OleW 2,3-keto-
reductase. The lack of formation of 4-deacetyl-LCHR-
TCMC with pFL945 prompted us to replace then the
eryBIII C-methyltransferase gene with themtmC C-meth-
yltransferase. The rationale behind this exchange was
that, after the 2-deoxygenation steps catalyzed by OleV
and OleW, intermediate NDP-4-keto-2,6-dideoxy-D-
glucose should be formed, the natural substrate of
C-methyltransferase MtmC during D-mycarose biosyn-
thesis in the mithramycin pathway [12]. Upon introduc-
tion of the resultant plasmid (pFL947; Figure 2) into
S. lividans 16F4, three major peaks (peaks 4, 5, and 8
in Figure 3F) were detected by HPLC-MS, whose m/z
values (603, 589, and 617) were consistent with the for-
mation of 4-deacetyl-LCHR-TCMC, D-olivosyl-tetra-
cenomycin C (DOLV-TCMC) and 4-deacetyl-LCHR-ELM.
Confirmation of the structure of 4-deacetyl-LCHR-
Chemistry & Biology
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sHPLC and subsequent elucidation of its structure by
NMR (see below). The 4-deacetyl-L-CHR- (both deriva- a
ttives taken together) and D-OLV-derivatives repre-
sented approximately 32% and 37%, respectively, of i
othe total tetracenomycins produced.
Taking together all experiments shown above, we s
Ecan draw several conclusions on the functional activity
and substrates of some sugar biosynthesis enzymes r
t(Figure 4).
i
tMtmC: It has been proposed that themtmC gene codes
sfor a C-3 methyltransferase in D-mycarose biosynthesis
[12]. Formation of 4-deacetyl-L-CHR-containing tetra-
cenomycin derivatives by the recombinant strain har- S
boring pFL947 confirms this role for MtmC, acting on T
NDP-4-keto-2,6-dideoxyglucose, which presumably is f
its natural substrate. T
EryBIII: The EryBIII C-methyltransferase probably acts s
on a D-sugar intermediate with a C-3 hydroxyl group e
in axial configuration, as it was demonstrated for its
homologous TylC3 in L-MYC biosynthesis in the tylosin s
pathway [19]. If this was not the case, and EryBIII could s
act on an L-intermediate, L-MYC would have been pro- s
duced using pFL821, since the action of OleW and OleL s
renders an appropriate L-intermediate. Thus, since no c
L-MYC was synthesized with pFL821, the possibility of n
EryBIII acting on an L-intermediate can be ruled out. T
Moreover, EryBIII cannot convert an NDP-2,6-deoxy-D- t
sugar substrate if it possesses an equatorial hydroxyl t
group at C-3 such as that produced by OleW. This con- 2
clusion follows from the result that no LCHR-TCMC is o
generated using pFL945, which contains eryBIII, how- 3
ever, LCHR-TCMC is generated when using pFL947, m
which contains mtmC instead. i
EryBVII: The fact that EryBIII acts on a D-sugar inter- p
mediate indicates that EryBVII causes C-5 epimeriza- t
tion acting on a 3-C-methylated substrate during L-MYC 4
biosynthesis in the erythromycin pathway. Furthermore, 4
EryBVII acts regardless of how C-3 is configurated, i.e., 1
on both a substrate with an equatorial methyl group or p
a substrate with an axial methyl group, leading to L
LCHR-TCMC when using pFL947 (Figure 4, blue) or to c
LMYC-ELM using pFL942 (Figure 4, red). c
l
K
fApproach to Construct a Plasmid that Could
Synthesize 2,3,4-Tridemethyl-L-Nogalose 4
iSeveral attempts were made to construct a plasmid di-
recting 2,3,4-tridemethyl-L-NOG biosynthesis. First, we c
wtook advantage of the previously constructed pFL946,
in which the oleV and eryBII genes were deleted (Figure 3
s2). This deletion was supposed to eliminate the deoxy-
genation step affecting C-2 and therefore potentially o
trendering 2,3,4-tridemethyl-L-NOG instead of L-MYC.
Using this construct, no formation of 2,3,4-tridemethyl- g
aL-nogalosyl-tetracenomycin C was observed when an-
alyzed by HPLC-MS. A second approach was done by a
replacing eryBIII with mtmC in pFL946 (Figure 2). Both
genes code for C-methyltransferases: mtmC involved 1
min the biosynthesis of a D-sugar and eryBIII in the bio-
synthesis of an L-sugar, and acting on intermediates t
Mwith different stereochemistry at C-3. We assumed,hen designing this construct, that the possible sub-
trate intermediate would be more appropriate for the
ctivity of MtmC than that of EryBIII. However, when
he corresponding construct (pFL954) was introduced
nto S. lividans 16F4, no LNOG-TCMC was found but
nly D-glucosyl-tetracenomycin C (DGLU-TCMC). This
ugar has been previously shown to be transferred by
lmGT when using other gene constructs [43]. These
esults suggest that either the C-methyltransferases or
he 4-ketoreductase (or both), are unable to act on the
ntermediates formed or, if the deoxysugar is formed,
he possibility cannot be discarded that it could not be
ubstrate for the ElmGT glycosyltransferase.
tructural Elucidation of the Compounds
wo of the compounds mentioned above were chosen
or structural elucidation: LMYC-ELM and LCHR-
CMC, since they were compounds not previously de-
cribed. Yields of these compounds in the fermentation
xperiments were 4 and 6 mg/l, respectively.
LMYC-ELM was identified from its 1H and 13C NMR
pectra in comparison to elloramycinone. The 1H NMR
pectrum (300 MHz, in d6-acetone) of LMYC-ELM
hows all signals of elloramycinone, except the 8-OH
ignal. The only significantly shifted signal of the agly-
on moiety is 7-H (δ 7.78 versus δ 7.43 in elloramyci-
one) because of the nearby attached sugar moiety.
he 1H NMR signals of the sugar moiety consist of
hree spin systems observable in the H,H-COSY spec-
rum, one stretching from the anomeric 1#-H (δ 6.00) to
#-H2 (δ 2.14 and δ 2.26), the second from 6#-H3 (δ 1.20)
ver 5#-H (δ 3.81) to 4#-H (δ 3.09), the third being the
#-CH3 singlet (δ 1.28). This is consistent with a sugar
oiety containing a 3-methyl branch. The stereochem-
stry of the sugar moiety follows from the coupling
attern observed for each sugar proton. For instance,
he large diaxial coupling of 10 Hz between 5#-H and
#-H indicates that both the 5#-CH3 group as well as
-OH are in equatorial position, and the pattern of
#-H (d, J = 3.5 Hz) is in agreement with its equatorial
osition and therefore proves an α-glycosidically linked
-sugar, considering that ElmGT (like most streptomy-
ete GTs) follows a mechanism inverting the anomeric
onfiguration of the NDP-sugar-cosubstrate, thus be-
ongs to the GT-1 family and is in agreement with
lyne's rule [51]. The R-configuration of C-3# was con-
irmed by 2D-NOESY cross-couplings of 3#-CH3 with
#-H, 2#-Ha, and 6#-H3, which is only possible if 3#-CH3
s in an equatorial position, while no NOE-coupling
ould be observed between 5#-H and 3#-CH3 as one
ould have expected, if C-3# were S-configurated (with
#-CH3 being in an axial position). An NOE effect ob-
erved between 7-H and 1#-H also confirms the regi-
chemistry of the glycosidic linkage. These data prove
hat the sugar moiety of LMYC-ELM is indeed 8-O-α-
lycosidically linked L-mycarose. The 13C NMR data
re also in agreement with this conclusion. All the 1H
nd 13C NMR data of LMYC-ELM are listed in Table 1.
LCHR-TCMC was also identified from its HPLC-MS,
H and 13C NMR data in comparison with tetraceno-
ycin C, elloramycinone, and known 8-glycoslyated
etracenomycins. From the above-mentioned HPLC-
S data, it was evident that LCHR-TCMC contains
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1715Table 1. 1H and 13C NMR Data of LMYC-ELM and LCHR-TCMC in d6-Acetone
LMYC-ELM LCHR-TCMC
1H (300 MHz), 1H (300 MHz),
Position multiplicity (J in Hz) 13C (100 MHz) multiplicity (J in Hz) 13C (100 MHz)
1 — 189.0 — 190.8
2 5.49 s 101.1 5.63 s 99.3
3 — 173.0 — 176.1
3-OCH3 3.78 s 55.1 3.84 s 56.7
4 4.88 s 69.1 5.06 s 69.9
4-OH 4.98 sa — 5.01 br sb —
4a — 76.3 — 79.2
4a-OH 5.31 sa — 5.14 br sb —
5 — 193.3 — 194.2
5a — 140.5 — 140.5
6 7.99 s 120.5 7.99 s 120.6
6a — 131.0 — 130.0
7 7.55 s 111.1 7.75 s 111.4
8 — 155.2 — 155.2
9 — 128.4 — 128.4
9-CO — 168.3 — n.o.d
9-OCH3 3.96 s 52.4 3.96 s 52.2
10 — 136.5 — 137.7
10-CH3 2.86 s 20.4 2.84 s 20.3
10a — 120.5 — 121.1
11/11-OH 14.03 sc 167.7 14.00 sc 167.6
11a — 110.0 — 110.9
12 — n.o.d — 197.3
12a/12a-OH — 85.0 10.43 sc 81.5
12a-OCH3 3.59 s 56.4 — —
1# 6.0 br d (3.5) 96.1 5.97 br d (3.5) 96.6
2#/2#-Ha 2.14 dd (15, 3.5) 40.9 2.14 dd (15, 3.5) 43.1
2#-He 2.26 dd (15, 1) — 2.19 dd (15, 1) —
3#/3#-OH 3.31 br sa 66.5e 5.78 br sb 69.0f
3#-CH3 1.28 s 25.7 1.43 s 21.8
4# 3.09 d (9.5) 70.1e 3.31 d (9.5) 70.1f
4#-OH 3.21 br sa — 4.20 br sb —
5# 3.81 dq (9.5, 6) 66.5e 3.64 dq (9.5, 6) 69.9f
6#/6#-H3 1.20 d (6) 17.7 1.22 d (6) 17.9
δ in ppm relative to TMS.
aExchangeable with D2O, assignments interchangeable.
bExchangeable with D2O, assignments interchangeable.
cNot observed.
dExchangeable by D2O.
eAssignments interchangeable.
fAssignments interchangeable.8-demethyltetracenomycin C, not elloramycinone, as
its aglycon moiety (note that tetracenomycin C (TCMC)
and elloramycinone are structural isomers, which only
differ in the position of one of their OCH3 groups, which
is at 12a-position in elloramycinone instead of in
8-position in TCMC). This was confirmed by the 1H
NMR spectrum, in which no 12a-OCH3 group, but a
12a-OH group (δ 10.43) was found along with all other
signals representing this aglycon (see Table 1). The 1H
NMR signals of the sugar moiety are in agreement with
the expected α-L-chromose B (α-L-olivomycose); like
in LMYC-ELM (above), the H,H-COSY spectrum shows
three spin systems, (1) 1#-H (δ 5.97) to 2#-H2 (δ 2.14 and
2.19), (2) 6#-H3 (δ 1.22) over 5#-H (δ 3.64) to 4#-H (δ 3.31),
and (3) the 3-CH3 singlet (δ 1.43). A large diaxial cou-
pling between 4#-H and 5#-H of 9.5 Hz indicates these
two protons to be in an axial position of a 4C1-confor-
mation of an L-configured chair. The small coupling (3.5
Hz) between the anomeric 1#-H and 2#-H indicates itsaα-glycosidic bondage, considering ElmGT belonging to
the GT-1 family of glycosyltransferases following Klyne's
rule [51]. The S-configuration of C-3# (= axial CH3-resi-
due) was already indicated by a small 4JH-H coupling
between 2#-Ha and 3#-CH3 observable in the H,H-COSY
spectrum, but is unambiguously proven by the 2D-
NOESY spectrum, which shows a strong coupling be-
tween 5#-H and 3#-CH3. The 2D-NOESY spectrum also
shows a coupling between 7-H and 1#-H, confirming
the linkage position of the sugar moiety at 8-O. The 13C
NMR data are also in agreement with these conclu-
sions. All the 1H and 13C NMR data of LCHR-TCMC are
also listed in Table 1.
Antitumor Activity
The antitumor activity of the glycosylated tetraceno-
mycins was tested against three tumor cell lines. Com-
pilation of the average GI50 values showed that similar
to the original compound elloramycin, all the com-
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1716Ppounds had very low antitumor activity, being inactive
Sat concentrations below 10–5 M. The exception was
pLMYC-ELM, which showed antitumor activity above a
concentration 10–6 M. This indicates that substitution
of the original sugar residue by L-MYC improves the
antitumor activity of these compounds. Probably the
presence and orientation of the methyl group at C3 of
L-MYC is related to this improvement in the antitumor
activity of LMYC-ELM.
Significance
Glycosylation of natural products is usually very im-
portant for their biological activity. Therefore, altering
the sugar profile may improve the bioactivity or phar-
Dmacological properties of the parent molecules. We
nhave, to our knowledge, successfully constructed for
5
the first time plasmids directing the biosyntheses of a
branched NDP-deoxysugars. Such sugars play key r
Groles for drug-target interactions of many biologically
9active natural products, such as the macrolide antibi-
aotics erythromycin A, tylosin, and pikromycin, or the
aaureolic acid anticancer drugs olivomycin, mithra-
5
mycin, and chromomycin. These plasmids allow for r
the pathway-engineered drug design of novel deriva- a
itives of glycosylated natural products, if glycosyl-
transferases are present, which show flexibility toward
Ptheir NDP-sugar donor substrate. The proof of concept
pwas given here using the well established, NDP-sugar-
Acosubstrate-flexible glycosyltransferase ElmGT to
(
engineer novel glycosylated tetracenomycin deriva- g
tives. (
i
p
Experimental Procedures F
c
Microorganisms, Culture Conditions, and Vectors g
Streptomyces antibioticus ATCC11891 (oleandomycin producer), f
Streptomyces argillaceus ATCC12956 (mithramycin producer), and o
Saccharopolyspora erythraea NRRL2338 (erythromycin producer) r
were used as sources of DNA. cosAR7 [11], pLN2, and pLNBIV w
[34] were used as sources of sugar DNA cassettes. Streptomyces a
lividans 16F4 [42] was used as host for gene expression. Growth S
was carried out on trypticase soy broth (TSB; Oxoid) or R5A me- i
dium [52] for product isolation. For sporulation, we used agar w
plates containing medium A [52] for 7 days at 30°C. Escherichia g
coli DH10B (Invitrogen) was used as a host for subcloning and it B
was grown at 37°C in TSB medium. pCRBlunt (Invitrogen), pUC18, a
and pIAGO [8] were used as vectors for subcloning experiments
and DNA sequencing. When antibiotic selection of transformants p
was needed, 50 g/ml of thiostrepton, 25 g/ml of apramycin, 50 m
g/ml of kanamycin, or 100 g/ml of ampicillin were used.
P
SDNA Manipulation and Sequencing
gPlasmid DNA preparations, restriction endonuclease digestions, al-
skaline phosphatase treatments, ligations, and other DNA manipula-
stions were according to standard procedures for Streptomyces [53]
and for E. coli [54]. Sequencing was performed by using the di-
deoxynucleotide chain-terminator method [55] and the Thermo M
HSequenase Labeled Primer Cycle Sequencing Kit with 7-deaza-
dGTP (Amersham Biosciences). Both DNA strands were sequenced u
swith primers supplied in the kits or with internal oligoprimers (18-
mer) using an ALF-express automatic DNA sequencer (Amersham t
aBiosciences). Computer-assisted database searching and se-
quence analyses were carried out using the University of Wisconsin s
rGenetics Computer Group programs package [56] and the BLAST
program [57]. WCR Amplification
everal genes were amplified by PCR using the following oligo-
rimers.
oleL: FL-oleL-up, 5#-AAAATTAATTAAAATTCGGCAGAATCGG
GATCG-3#; FL-oleL-rp, 5#-AAAATCTAGATCACGGGCCGGTCC
CACGC-3#.
eryBII: FL-eryB2-up, 5#-AAAAGTTAACGCCCGCAGGAAGGAGA
GAACC-3#; FL-eryB2-rp, 5#-AAAAACTAGTCTTTCTCGGTTCCT
CTTGTGC-3#.
eryBVII: FL-eryB7-up, 5#-GGTTAATTAACTGCGCGGAAGGTGAA
CCGG-3#; FL-eryB7-rp, 5#-AATCTAGAACCAAGGCCACCGAGGT
CGC-3#.
mtmC: FL-mtmC-up, 5#-AAAAGCTAGCGCGCGGCGCCTTCCC
CTGTGACC-3#; FL-mtmC-rp, 5#-TTAATTAAGTTCGTCGTCCG
TGCCACGGTCACTCC-3#.
PCR reaction conditions were as follows: 100 ng of template
NA was mixed with 30 pmol of each primer and 1.25 U of Plati-
um-Pfx DNA Polymerase (Invitrogen) in a total reaction volume of
0 l containing 1 mM MgSO4, 0.3 mM of each dNTP, 1× Pfx-buffer,
nd in some cases PCRx Enhancer Solution. The polymerization
eactions were performed in a thermocycler (PT-100, MJ Research).
eneral conditions for PCR amplification were as follows: 2 min at
4°C; 30 cycles composed of 30 s at 94°C; 1 min at the primer
nnealing temperature and 80 s at 68°C; 5 min at 68°C; and 15 min
t 4°C. Primer annealing temperatures for the different genes were
3°C, 56°C, 73°C, and 60°C for oleL, eryBII, eryBVII, and mtmC,
espectively. The PCR products were purified with GFX PCR DNA
nd Gel Band Purification Kit (Amersham Biosciences), subcloned
nto pCRBlunt, and sequenced.
lasmid Constructs
FL0DE
2.8 kb PstI-SphI fragment from cosAR7, containing the mtmD
NDP-glucose synthase) and mtmE (NDP-4,6-glucose dehydratase)
enes [11] was subcloned into pUC18 and then rescued as an XbaI
using this site from the polylinker)-SphI fragment, and subcloned
nto the same sites of pIAGO, downstream of the ermE promoter.
FL821
or constructing this plasmid, pLNBIV was chosen as the starting
onstruct. It was first digested with NheI and PacI and the eryBIII
ene flanked by the same restriction sites replaced the released
ragment. Then, the PacI-XbaI fragment, containing oleL, oleS, and
leE genes, was replaced by the oleL gene flanked by the same
estriction sites, generating plasmid pFL820. In parallel, pFL0DE
as digested with XbaI, and after filling ends with Klenow polymer-
se, religated to eliminate the XbaI site. Then, the 3.1 kb EcoRI-
phI fragment blunt-ended with the Klenow fragment and contain-
ng the mtmD and mtmE genes under the control of the ermEp,
as subcloned into the unique blunt-ended HindIII site of pFL820,
enerating pFL821. In this final construct, oleV, oleW, eryBIV, ery-
III, and oleL are under the control of the ermE*p, and the mtmD
nd mtmE genes are divergently transcribed from an ermEp.
Several other constructs were made derived from plasmid
FL821, as shown in Figure 2 (for details, see Table S1 in Supple-
ental Data).
roduction Conditions and Chromatographic Techniques
pores of S. lividans 16F4 containing the different constructs were
rown in R5A medium according to conditions previously de-
cribed [34]. HPLC analyses were performed as previously de-
cribed [34].
ass Spectra and NMR Analysis
PLC-MS analysis of the glycosylated compounds was carried out
sing chromatographic equipment coupled to a ZQ4000 mass
pectrometer (Waters-Micromass), using electrospray ionization in
he positive mode, with a capillary voltage of 3 kV and a cone volt-
ge of 20 V. Chromatographic conditions were as previously de-
cribed [34], except for the column size (2.1 × 150 mm) and flow
ate (0.25 ml/min). A SymmetryPrep C18 column (7.8 × 300 mm,
aters) was used for compound purification, with acetonitrile and
Glycosylation in Bioactive Compounds
17170.1% trifluoroacetic acid as solvents. The new compound LCHR-
TCM was eluted in isocratic mode with 32.5% acetonitrile, while
40% acetonitrile was used for LMYC-ELM. Standards with pure
compounds were used for L-olivosyl, L-digitoxosyl-, permethylated
L-rhamnosyl-, D-olivosyl-, and D-glucosyl-8-demethyl-tetraceno-
mycin C and -elloramycinone comparisons.
NMR spectra were recorded on Varian Inova 300 and Varian In-
ova 400 NMR spectrometers at magnetic field strengths of 7.05 T
and 9.40 T, respectively. The δ values were adjusted on the solvent
peaks (d6-acetone, δ 2.05 and δ 29.9 ppm for 1H and 13C NMR,
respectively), and standard conditions were used for the 2D-NMR
spectra.
Antitumor Tests
The antitumor activity of the compounds was tested against tumor
cell lines of breast (MDA-MB-231), NSCL (A549), and colon (HT-29).
Quantitative measurement of cell growth and viability was carried
out by using a colorimetric type of assay, using sulforhodamine
reaction [58].
Supplemental Data
A table with the nucleotide sequences of the primers used for PCR
amplification of the different genes and a table with a list of plasmid
constructs are available online at http://www.chembiol.com/cgi/
content/full/11/12/1709/DC1/.
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